iSERA Lifesciences Issues Corrigendum to Postal Ballot Notice on Preferential Share Issue; Re-opening E-Voting Scheduled

iSERA Lifesciences Issues Corrigendum to Postal Ballot Notice on Preferential Share Issue; Re-opening E-Voting Scheduled​

iSERA Lifesciences Ltd., formerly Covidh Technologies Limited, has issued a Corrigendum to its Postal Ballot Notice dated April 21, 2026. The corrigendum pertains to the proposed preferential issue of equity shares for consideration other than cash (Share Swap) and addresses amendments and provides extensive additional disclosures to all members.

The document outlines key changes related to the allotment process under Item No. 7 of the Postal Ballot Notice.

Key Amendments to Preferential Issue Details​

One significant amendment corrects a typographical error in the Explanatory Statement regarding the intended subscription of shares. The notice previously reflected an entry for Dhairyasheel Vasantrao Yadav having "4,50,50" equity shares to be allotted. This is corrected to 4,50,500 shares.

The revised details for this allotment are as follows:


In addition to the correction, a comprehensive person-wise disclosure of the post-preferential issue capital percentage has been introduced for Item No. 7, replacing previous general statements in the Explanatory Statement.

The distribution of percentages among allottees is detailed across various groups of investors:


The list of allottees continues across multiple sections, detailing the shareholding percentage for each participant:


The full list of allottees, including investors ranging from entities like Nav Capital VCC and M7 Global Fund PCC to individuals such as Amit J Dholakia HUF and superstar recognition for Jasprit J Bumrah, is provided in the Corrigendum detailing their respective percentage holdings against the post-preferential issue capital.

Control Status and Re-opening of E-Voting​

The company has confirmed that there will be no change in the management or control of iSERA Lifesciences Ltd. following the Preferential Issue. The existing Promoters will continue to serve as the Promoters, ensuring continuity in the management structure.

Crucially, the Corrigendum stipulates that all votes cast by Members on Item No. 7 during the original e-voting window (April 22, 2026, to May 21, 2026) stand cancelled and will not be considered for determining the outcome of Item No. 7. However, votes cast on Items Nos. 1 through 6 from the original period remain valid.

To ensure all members are afforded an opportunity to vote on this item after reviewing the amendments, the Postal Ballot e-voting process for Item No. 7 has been re-opened.

Re-opening E-Voting Details​

Members of the Company as of April 17, 2026, who receive the Corrigendum are entitled to cast their votes afresh on this item. The revised voting schedule is as follows:


The corrigendum is available on the company's website and through the e-voting platform provided for members.

Stock Price Movement​

As the market concluded on Thursday, shares of iSERA Lifesciences Ltd settled at ₹124.17, registering a 2.00% gain. The shares maintained a completely locked range throughout the session, with the intraday high and low stabilizing precisely at ₹124.17.